New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - colestyramine 0.851 g/g (4g anhd cholestyramine resin / 4.7g questran lite powder);   - powder for oral suspension - 4.7 g - active: colestyramine 0.851 g/g (4g anhd cholestyramine resin / 4.7g questran lite powder)   excipient: aspartame citric acid colloidal silicon dioxide orange flavour 059107 agep0551 propylene glycol alginate xanthan gum - reduction of serum cholesterol levels and prevention of coronary heart disease. questran is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoproteins). questran lite may be useful to lower elevated cholesterol that occurs in patients with combined hypercholesterolemia and hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern.

USA - engelsk - NLM (National Library of Medicine)

par pharmaceutical, inc. - cholestyramine (unii: 4b33bgi082) (cholestyramine - unii:4b33bgi082) - cholestyramine 4 g in 9 g - 1) questran (cholestyramine for oral suspension usp), is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [ldl] cholesterol) who do not respond adequately to diet. questran may be useful to lower ldl cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. prior to initiating therapy with quest

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - cholestyramine -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - colestyramine, quantity: 850 mg/g - powder, oral - excipient ingredients: xanthan gum; colloidal anhydrous silica; citric acid; aspartame; propylene glycol alginate; flavour - indications as at 1 january 1991 : 1. reduction of serum cholesterol levels and prevention of coronary heart disease. questran lite is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoproteins). questran lite may be useful to lower elevated cholesterol that occurs in patients with combined hypercholesterolemia and hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. 2. relief of pruritus associated with partial biliary obstruction. patients with primary biliary cirrhosis may exhibit elevated serum cholesterol as part of their disease. when cholestyramine is used to treat the pruritus of partial biliary obstruction, it may lower serum cholesterol levels, produce no change, or cause rapid escape from a temporary lowering to pre-treatment levels or rebound. 3. relief of diarrhoea following ileal resection or ileal disease (cholerrhoeic enteropa

Irland - engelsk - HPRA (Health Products Regulatory Authority)

bristol-myers squibb (holdings) limited - colestyramine - powder for oral suspension - 4 grams - bile acid sequestrants

Irland - engelsk - HPRA (Health Products Regulatory Authority)

cheplapharm arzneimittel gmbh - colestyramine resin - powder for oral suspension - 4 g/sachet - bile acid sequestrants; colestyramine

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - colestyramine anhydrous - powder - 4gram

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - colestyramine anhydrous - powder - 4gram

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - colestyramine 0.444 g/g (4g anhydrous cholestyramine resin / 9g questran powder) - powder for oral suspension - 9 g - active: colestyramine 0.444 g/g (4g anhydrous cholestyramine resin / 9g questran powder) excipient: acacia citric acid orange flavour 059107 agep0551 polysorbate 80 propylene glycol alginate quinoline yellow sucrose

Sør-Afrika - engelsk - South African Health Products Regulatory Authority (SAHPRA)

bm_squib -